tbuckley/cabot-search huggingface dataset:
A Randomized Trial Comparing Weekly With Every Second Week Sharp Debridement in People With Diabetes-Related Foot Ulcers Shows Similar Healing Outcomes: Potential Benefit to Resource Utilization
Authors: Vanessa L. Nube, Jessica M. White, Kate Brewer, Danielle Veldhoen, Cindy Meler, Georgina Frank, Kate Carroll, Jill Featherston, Jacqueline Batchelor, Val Gebski, Jennifer A. Alison, Stephen M. Twigg
Journal: Diabetes Care (2021)
P14.07 PERLA: Randomized Phase II Trial of Dostarlimab + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC
Authors: A. Spira, S.M. Lim, F. Griesinger, F. De Marinis, T. Mccarthy, N. Huseinovic, S. O'Donnell, J.S. Ahn
Journal: Journal of Thoracic Oncology (2021)
Artificial intelligence enables comprehensive genome interpretation and nomination of candidate diagnoses for rare genetic diseases
Authors: Francisco M. De La Vega, Shimul Chowdhury, Barry Moore, Erwin Frise, Jeanette McCarthy, Edgar Javier Hernandez, Terence Wong, Kiely James, Lucia Guidugli, Pankaj B. Agrawal, Casie A. Genetti, Catherine A. Brownstein, Alan H. Beggs, Britt-Sabina Löscher, Andre Franke, Braden Boone, Shawn E. Levy, Katrin Õunap, Sander Pajusalu, Matt Huentelman, Keri Ramsey, Marcus Naymik, Vinodh Narayanan, Narayanan Veeraraghavan, Paul Billings, Martin G. Reese, Mark Yandell, Stephen F. Kingsmore
Journal: Genome Medicine (2021)

Clinical interpretation of genetic variants in the context of the patient's phenotype is becoming the largest component of cost and time expenditure for genome-based diagnosis of rare genetic diseases. Artificial intelligence (AI) holds promise to greatly simplify and speed genome interpretation by integrating predictive methods with the growing knowledge of genetic disease. Here we assess the diagnostic performance of Fabric GEM, a new, AI-based, clinical decision support tool for expediting genome interpretation.We benchmarked GEM in a retrospective cohort of 119 probands, mostly NICU infants, diagnosed with rare genetic diseases, who received whole-genome or whole-exome sequencing (WGS, WES). We replicated our analyses in a separate cohort of 60 cases collected from five academic medical centers. For comparison, we also analyzed these cases with current state-of-the-art variant prioritization tools. Included in the comparisons were trio, duo, and singleton cases. Variants underpinning diagnoses spanned diverse modes of inheritance and types, including structural variants (SVs). Patient phenotypes were extracted from clinical notes by two means: manually and using an automated clinical natural language processing (CNLP) tool. Finally, 14 previously unsolved cases were reanalyzed.GEM ranked over 90% of the causal genes among the top or second candidate and prioritized for review a median of 3 candidate genes per case, using either manually curated or CNLP-derived phenotype descriptions. Ranking of trios and duos was unchanged when analyzed as singletons. In 17 of 20 cases with diagnostic SVs, GEM identified the causal SVs as the top candidate and in 19/20 within the top five, irrespective of whether SV calls were provided or inferred ab initio by GEM using its own internal SV detection algorithm. GEM showed similar performance in absence of parental genotypes. Analysis of 14 previously unsolved cases resulted in a novel finding for one case, candidates ultimately not advanced upon manual review for 3 cases, and no new findings for 10 cases.GEM enabled diagnostic interpretation inclusive of all variant types through automated nomination of a very short list of candidate genes and disorders for final review and reporting. In combination with deep phenotyping by CNLP, GEM enables substantial automation of genetic disease diagnosis, potentially decreasing cost and expediting case review.
Recent Advances in Hypoxia‐Overcoming Strategy of Aggregation‐Induced Emission Photosensitizers for Efficient Photodynamic Therapy
Authors: Huan Chen, Yingpeng Wan, Xiao Cui, Shengliang Li, Chun‐Sing Lee
Journal: Advanced Healthcare Materials (2021)

Abstract Hypoxia is an inherent physiologic barrier in the microenvironment of solid tumor and has badly restricted the therapeutic effect of photodynamic therapy (PDT). Meanwhile, the photosensitizer (PS) agents used for PDT applications regularly encounter the tiresome aggregation‐caused quenching effect that seriously decreases the production efficiency of cytotoxic reactive oxygen species. The aggregation‐induced emission (AIE) PSs with antiquenching characteristics in the aggregate state are considered as a promising tool for achieving highly efficient PDT applications, and plenty of studies have widely demonstrated their advantages in various diseases. Herein, the recent progress of AIE PSs in the battle of antitumor hypoxia issue is summarized and the practical molecular principles of hypoxia‐overcoming AIE PSs are highlighted. According to the hypoxia‐overcoming mechanism, these representative cases are divided into low O 2 ‐dependent (type I PDT) and O 2 ‐dependent tactics (mainly including O 2 ‐enrichment type II PDT and combination therapy). Furthermore, the underlying challenges and prospects of AIE PSs in hypoxia‐overcoming PDT are proposed and thus expect to promote the next development of AIE PSs.
P29.05 Gross Tumor Volume Contouring Variations in Radiation Therapy of Non-Small Cell Lung Cancer
Authors: Y. Liu, J.L. Liu, Z. Tan, X. Jiang, L. Wang, Y. Lu, X.L. Fu, Q. Song, L. Zhao, S. Yuan, N. Bi, Y. Xu, Z. Zhu, G. Zhu, J. Li, C. Xie, X. Ma, G. Xiao, H. Ge, H. Liu, J. Zhao, J. Liang, Q. Shen, Q. Xu, R. Liu, S. Zhou, W. Kong, W. Zhong, X. Jin, Y. Wang, Y. Jiang, Z. Fu, Y. Xie, J. Cai, Z. Li, M. Machtay, W. Curran, F.M. Kong
Journal: Journal of Thoracic Oncology (2021)
Abstract 10863: Risk Variation Within Very High-risk Group Among Patients With Atherosclerosis Cardiovascular Disease: The Atherosclerosis Risk in Communities (ARIC) Study
Authors: Ye Jin Mok, Shoshana H Ballew, Brandon Stacey, Joseph Rossi, Silvia Koton, Anna Kucharska-Newton, Patricia P Chang, Josef Coresh, Wayne D Rosamond, Kunihiro Matsushita
Journal: Circulation (2019)

Background: To guide new PCSK9 inhibitors, the AHA/ACC 2018 Cholesterol Guideline has adopted a new concept of “very high-risk” and “high-risk” for patients with atherosclerotic cardiovascular dise...
Pre-chemotherapy nutritional status and chemotherapy response: An observational study
Authors: R. Rao, N. Saha, V. Mani, R. Amritanshu, R. Geetha, N. Radheshyam, S. Patil, H.P. Shashidhara, T.C. Satheesh, V. Agarwal, B.S. Ajaikumar
Journal: Annals of Oncology (2017)
Screening for Health-Related Social Needs in Pediatric Value-Based Care
Authors: Thuy-Vi Nguyen, Richard J. Chung, Charlene Wong
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Perianal Chancres of Primary Syphilis
Authors: Herbert Castillo Valladares, Errol Craig, Kenneth A. Katz
Journal: JAMA Dermatology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer
Authors: Duncan R. McKenzie, Miguel Muñoz-Ruiz, Leticia Monin, Thanussuyah Alaguthurai, Thomas Lechmere, Sultan Abdul-Jawad, Carl Graham, Emily Pollock, Rosalind Graham, Kamila Sychowska, Jeffrey Seow, Catherine Tremain, Charalampos Gousis, Clara Domingo-Vila, Jack Cooper, Jennifer Vidler, Kasia Owczarczyk, Angela Swampillai, Hartmut Kristeleit, Michael H. Malim, Paul Fields, Piers E.M. Patten, Sophie Papa, Bernard V. North, Timothy Tree, Katie J. Doores, Adrian C. Hayday, Sheeba Irshad
Journal: Cancer Cell (2021)
P02.05 Yield of Tumor Samples With A Guide-sheath in Endobronchial Ultrasound Transbronchial Biopsy For Non-small Cell Lung Cancer
Authors: N. Katsurada, M. Tachihara, N. Jimbo, M. Yamamoto, J. Yoshioka, C. Mimura, N. Takata, H. Sato, K. Furukawa, T. Otoshi, M. Yumura, T. Kiriu, Y. Yasuda, T. Tanaka, T. Nagano, Y. Nishimura, K. Kobayashi
Journal: Journal of Thoracic Oncology (2021)
P31.05 SARS-CoV-2 and Lung Cancer: Pandemic Impact in Diagnosis, Staging and Management
Authors: M.T. Tsukazan, G.F. Schneider, L. Bittencourt Hinrichsen, M. Iglesias, P.A. Schulze, R. Paulino, T. Menegaz, A. Vigo, J. Schmitt, J. Figueiredo Pinto
Journal: Journal of Thoracic Oncology (2021)
The Neighborhood of the Spike Gene Is a Hotspot for Modular Intertypic Homologous and Nonhomologous Recombination in Coronavirus Genomes
Authors: Marios Nikolaidis, Panayotis Markoulatos, Yves Van de Peer, Stephen G Oliver, Grigorios D Amoutzias
Journal: Molecular Biology and Evolution (2021)

Abstract Coronaviruses (CoVs) have very large RNA viral genomes with a distinct genomic architecture of core and accessory open reading frames (ORFs). It is of utmost importance to understand their patterns and limits of homologous and nonhomologous recombination, because such events may affect the emergence of novel CoV strains, alter their host range, infection rate, tissue tropism pathogenicity, and their ability to escape vaccination programs. Intratypic recombination among closely related CoVs of the same subgenus has often been reported; however, the patterns and limits of genomic exchange between more distantly related CoV lineages (intertypic recombination) need further investigation. Here, we report computational/evolutionary analyses that clearly demonstrate a substantial ability for CoVs of different subgenera to recombine. Furthermore, we show that CoVs can obtain—through nonhomologous recombination—accessory ORFs from core ORFs, exchange accessory ORFs with different CoV genera, with other viruses (i.e., toroviruses, influenza C/D, reoviruses, rotaviruses, astroviruses) and even with hosts. Intriguingly, most of these radical events result from double crossovers surrounding the Spike ORF, thus highlighting both the instability and mobile nature of this genomic region. Although many such events have often occurred during the evolution of various CoVs, the genomic architecture of the relatively young SARS-CoV/SARS-CoV-2 lineage so far appears to be stable.
Effect of Moderate vs Mild Therapeutic Hypothermia on Mortality and Neurologic Outcomes in Comatose Survivors of Out-of-Hospital Cardiac Arrest
Authors: Michel Le May, Christina Osborne, Juan Russo, Derek So, Aun Yeong Chong, Alexander Dick, Michael Froeschl, Christopher Glover, Benjamin Hibbert, Jean-François Marquis, Sophie De Roock, Marino Labinaz, Jordan Bernick, Shawn Marshall, Ronnen Maze, George Wells
Journal: JAMA (2021)

<h3>Importance</h3> Comatose survivors of out-of-hospital cardiac arrest experience high rates of death and severe neurologic injury. Current guidelines recommend targeted temperature management at 32 °C to 36 °C for 24 hours. However, small studies suggest a potential benefit of targeting lower body temperatures. <h3>Objective</h3> To determine whether moderate hypothermia (31 °C), compared with mild hypothermia (34 °C), improves clinical outcomes in comatose survivors of out-of-hospital cardiac arrest. <h3>Design, Setting, and Participants</h3> Single-center, double-blind, randomized, clinical superiority trial carried out in a tertiary cardiac care center in eastern Ontario, Canada. A total of 389 patients with out-of-hospital cardiac arrest were enrolled between August 4, 2013, and March 20, 2020, with final follow-up on October 15, 2020. <h3>Interventions</h3> Patients were randomly assigned to temperature management with a target body temperature of 31 °C (n = 193) or 34 °C (n = 196) for a period of 24 hours. <h3>Main Outcomes and Measures</h3> The primary outcome was all-cause mortality or poor neurologic outcome at 180 days. Neurologic outcome was assessed using the Disability Rating Scale, with poor neurologic outcome defined as a score greater than 5 (range, 0-29, with 29 being the worst outcome [vegetative state]). There were 19 secondary outcomes, including mortality at 180 days and length of stay in the intensive care unit. <h3>Results</h3> Among 367 patients included in the primary analysis (mean age, 61 years; 69 women [19%]), 366 (99.7%) completed the trial. The primary outcome occurred in 89 of 184 patients (48.4%) in the 31 °C group and in 83 of 183 patients (45.4%) in the 34 °C group (risk difference, 3.0% [95% CI, 7.2%-13.2%]; relative risk, 1.07 [95% CI, 0.86-1.33];<i>P</i> = .56). Of the 19 secondary outcomes, 18 were not statistically significant. Mortality at 180 days was 43.5% and 41.0% in patients treated with a target temperature of 31 °C and 34 °C, respectively (<i>P</i> = .63). The median length of stay in the intensive care unit was longer in the 31 °C group (10 vs 7 days;<i>P</i> = .004). Among adverse events in the 31 °C group vs the 34 °C group, deep vein thrombosis occurred in 11.4% vs 10.9% and thrombus in the inferior vena cava occurred in 3.8% and 7.7%, respectively. <h3>Conclusions and Relevance</h3> In comatose survivors of out-of-hospital cardiac arrest, a target temperature of 31 °C did not significantly reduce the rate of death or poor neurologic outcome at 180 days compared with a target temperature of 34 °C. However, the study may have been underpowered to detect a clinically important difference. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT02011568
P61.03 Comparison of the Sensitivity of Different Screening Algorithms to Select Lung Cancer Patients for Screening in a Cohort of German Patients
Authors: J. Walter, D. Kauffmann-Guerrero, T. Muley, M. Reck, J. Fuge, A. Günther, R. Majeed, J. Dinkel, C. Schneider, K. Senghas, I. Watermann, S. Kobinger, I. Koch, F. Manapov, M. Thomas, K. Kahnert, H. Winter, J. Behr, M. Tammemagi, A. Tufman
Journal: Journal of Thoracic Oncology (2021)
Abstract 18183: Short-term Impact of Defibrillation Testing on Heart Failure Admission
Authors: Baris Akdemir, Balaji Krishnan, Venkatakrishna Tholakanahalli, David Benditt, Jian-Ming Li
Journal: Circulation (2015)

Introduction: SIMPLE trial showed that defibrillation testing (DT) is safe but does not improve shock efficacy or mortality. However, impact of DT on heart failure (HF) admission at 30 days is unclear. Objectives: The aim of this study was to compare mortality and HF admission of ICD recipients who underwent DT (DT+) compared with those who did not (DT-). Methods: In this retrospective study, we analyzed consecutive patients who received an ICD ( new implant or generator change ) with DT+ and DT- between January 2008 and May 2014 from our ICD registry. Primary endpoints were death ( 30 days and 1 year ) and HF admission ( 30 days) . Results: Of the 501 patients, 311 patients (62,1%) were in DT+ group vs 190 (37,9%) were in DT- group. The mean ages in DT+ and DT- were 66 ± 10 and 70 ± 10 respectively (p&lt;0.0001). DT- group had more generator change than DT+ group ( 61,1% versus 30,9%, p &lt; 0.0001). Other demographic features were not significantly different between two groups (Table 1). No significant difference in mortality was found between two groups at 30 days and 1 year. HF admission at 30 days was significantly higher in DT+ group than in DT- group ( 17,4 % versus 4,7%, p &lt; 0.0001) (Table 2). Conclusion: No short-term and long-term mortality were associated with DT, but DT was associated with increased HF admission at 30 days. Future prospective studies are needed to prove this association.
Emperor of the Empire
Authors: Margaret S. Bravo
Journal: New England Journal of Medicine (2021)

The glaring fluorescent lights pierce through my head as I walk down the dingy hallway that smells faintly of urine.I feel swollen.My skin is crawling and feels hot and cracked.A lone bead of sweat trickles down the front of my shirt, and I swear it smells of Southern Comfort.My eyes are on fire.I have never been so thirsty in my life.Or humiliated.The chief of my group -Medicine B -just laced into me in front of everyone for not ordering blood cultures on a patient newly admitted to rule out Pneumocystis carinii.Every fever of unknown origin patient was supposed to have them done.The man had died 4 hours later.It was evident that he was dying, the way he was Cheyne-Stokes breathing.I didn't want to cause any further pain or insult to him.Dr. Miles O'Sullivan thought differently: "Pull a stunt like that at again and you're out of the program!" he screamed at me in front of the entire team during morning rounds.How much did I freaking drink last night?How am I still upright?Why can't I remember?The slow roil of panic starts again.Walk, I tell myself.It was just a bad night.Alcoholics don't land prime NYC residencies or graduate at the top of their class.It's not like I drink every night.Nine a.m.Oh my god.It feels like 2 p.m. already.I'm not going to last through this day.Maybe one of the nurses will spot me some Tylenol.I should go to 2 Reiser -I asked on 4 last week.They'll notice if I ask again.My pager hits my thigh rhythmically as I walk.Pass by two more stations to round on eight patients and then I can take a smoke break.Maybe even sneak in a nap somewhere.In my 3 months of residency, I've learned every nook and cranny of the hospital.My beeper goes off.2530 is on the screen.I stop at a wall phone and dial the extension."Hi, this Victoria from Medicine B." I still feel funny about calling myself Doctor."Hi, this is Jill from 6 Michenburg, I need you here ASAP.A patient is trying to leave.I need you to start the against medical advice form.
High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy
Authors: Genghao Chen, Ellen L Shrock, Mamie Z Li, Jonathan M Spergel, Kari C Nadeau, Jacqueline A Pongracic, Dale T Umetsu, Rima Rachid, Andrew J MacGinnitie, Wanda Phipatanakul, Lynda Schneider, Hans C Oettgen, Stephen J Elledge
Journal: Cell Reports Medicine (2021)

Peanut allergy can result in life-threatening reactions and is a major public health concern. Oral immunotherapy (OIT) induces desensitization to food allergens through administration of increasing amounts of allergen. To dissect peanut-specific immunoglobulin E (IgE) and IgG responses in subjects undergoing OIT, we have developed AllerScan, a method that leverages phage-display and next-generation sequencing to identify the epitope targets of peanut-specific antibodies. We observe a striking diversification and boosting of the peanut-specific IgG repertoire after OIT and a reduction in pre-existing IgE levels against individual epitopes. High-resolution epitope mapping reveals shared recognition of public epitopes in Ara h 1, 2, 3, and 7. In individual subjects, OIT-induced IgG specificities overlap extensively with IgE and exhibit strikingly similar antibody footprints, suggesting related clonal lineages or convergent evolution of peanut-specific IgE and IgG B cells. Individual differences in epitope recognition identified via AllerScan could inform safer and more effective personalized immunotherapy.
Can Litigation Help Reduce Bullying?
Authors: Jonathan Todres
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
Authors: Jennifer J Gao, Joyce Cheng, Tatiana M Prowell, Erik Bloomquist, Shenghui Tang, Suparna B Wedam, Melanie Royce, Danielle Krol, Christy Osgood, Gwynn Ison, Rajeshwari Sridhara, Richard Pazdur, Julia A Beaver, Laleh Amiri-Kordestani
Journal: The Lancet Oncology (2021)
Ocular Biometric Risk Factors for Progression of Primary Angle Closure Disease
Authors: Benjamin Y. Xu, David S. Friedman, Paul J. Foster, Yu Jiang, Natalia Porporato, Anmol A. Pardeshi, Yuzhen Jiang, Beatriz Munoz, Tin Aung, Mingguang He
Journal: Ophthalmology (2021)